VEGFA antibody (Biotin)

Catalog No. ABIN7608405

This anti-VEGFA antibody is a Human Chimeric antibody detecting VEGFA in FACS. Suitable for Human.

Quick Overview for VEGFA antibody (Biotin) (ABIN7608405)

Target: VEGFA (Vascular Endothelial Growth Factor A (VEGFA))

Reactivity: Human

Host: Human, Rabbit

Clonality: Chimeric

Conjugate: This VEGFA antibody is conjugated to Biotin

Application: Flow Cytometry (FACS)

Clone: DMC276

Product Details anti-VEGFA Antibody (Biotin)

Purpose: Biotinylated Anti-VEGFA antibody(DMC276), IgG1 Chimeric mAb

Purification: Purified from cell culture supernatant by affinity chromatography

Isotype: IgG1

Application Details

Application Notes: Flow Cyt 1:100

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose is added as protectants before lyophilization.

Storage: -20 °C,-80 °C

Storage Comment: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

Expiry Date: 12 months

Target Details for VEGFA

Target: VEGFA (Vascular Endothelial Growth Factor A (VEGFA))

Alternative Name: VEGFA

Background: This gene is a member of the PDGF:VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site.

UniProt: P15692

Pathways: RTK Signaling, Glycosaminoglycan Metabolic Process, Regulation of Cell Size, Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Platelet-derived growth Factor Receptor Signaling, VEGFR1 Specific Signals, VEGF Signaling